Metformin Slowed Frailty and Turned Back Epigenetic Clocks in Two-Year Trial
Graded Moderate — two-year randomized placebo-controlled trial in 145 older adults with glucose intolerance, still a single modest-sized study not yet repeated.
- Design
- Preprint
- Participants
- 145
- Duration
- —
- Funding
- —
This study suggests metformin's anti-aging effects depend heavily on how you measure frailty.
Older adults with prediabetes took metformin or a placebo for two years. Those on metformin accumulated fewer health deficits over time, and two DNA-based age clocks in their blood ticked slower. The picture was mixed though: on the classic frailty checklist, metformin looked worse in year one, but only because the drug caused weight loss. It was well tolerated overall.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.